BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification


11/7/2008 7:42:08 AM

SAN DIEGO, Nov. 6 /PRNewswire/ -- Valor Medical, Inc., a medical device company that has developed a liquid embolic technology for the treatment of cerebral aneurysms, announced today that they have successfully raised $1.4 million in capital through a convertible debt offering. Valor's Chief Executive Officer, Clark Adams stated, "Valor's Board and shareholders had approved raising $1.4 million in capital that will be used to complete clinical trials needed for commercial approval in Europe. Reaching the $1.4 million limit went rather quickly and, unfortunately, could not accommodate all potential investors."

Valor also announced that they have received ISO 13485 certification. This certification is a major step toward commercialization in Europe. Mr. Adams explained that the ISO certification is needed before a medical device company can apply for the European CE Mark that must be received before they are allowed to sell product in Europe. Valor Medical expects to receive CE Mark late 2009 and will begin sales at that time.

"Clinical trial results to date have been positive and the reduction in surgery time is dramatic. The accumulated patient implant time to date has reached over 6.4 years," Mr. Adams announced. Valor Medical expects to sell product by the end of 2009 and will be raising additional capital as the company ramps up sales, marketing and distribution in Europe.

For additional information, visit Valor Medical's web site, http://www.valormedical.com

CONTACT: Clark Adams, CEO of Valor Medical, Inc., +1-858-643-1675

Web site: http://www.valormedical.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->